10-K: Helix Acquisition Corp. II Outlines Securities in Annual 10-K Filing

Helix Acquisition Corp. II details its outstanding Class A and Class B ordinary shares, preference shares, and related shareholder rights in its annual 10-K filing.

Summary

• Helix Acquisition Corp. II's 10-K filing describes the company's securities, including Class A and Class B ordinary shares and preference shares.
• As of March 10, 2025, there were 23,509,000 ordinary shares outstanding, consisting of 18,909,000 Class A ordinary shares and 4,600,000 Class B ordinary shares held by the Sponsor, Helix Holdings II LLC.
• Ordinary shareholders are entitled to one vote per share, with Class A and Class B shareholders voting together as a single class, except as required by law.
• The board of directors is divided into three classes, with directors serving three-year terms.
• The company may provide public shareholders with an opportunity to redeem their shares upon completion of an initial business combination.
• The Sponsor, officers, directors, and advisors have agreed to waive their redemption rights with respect to their founder shares and private placement shares.
• The company is working towards a business combination with BridgeBio Oncology Therapeutics (BBOT).
• If the company cannot complete a business combination within the specified timeframe, it will redeem public shares at a per-share price equal to the amount in the trust account.
• The company is subject to the rules of Nasdaq, requiring a business combination with a fair market value of at least 80% of the assets held in the Trust Account.
• The company is an emerging growth company and a smaller reporting company, which allows for certain exemptions from reporting requirements.

Sentiment

Score: 6

Explanation: The document is neutral in tone, providing factual information about the company's securities and operations. The sentiment is slightly positive due to the ongoing efforts to complete a business combination.

Positives

• The Sponsor, officers, directors, and advisors have agreed to waive their redemption rights on founder and private placement shares, demonstrating commitment.
• The company is actively pursuing a business combination with BridgeBio Oncology Therapeutics (BBOT).
• The company's classification as an emerging growth company and a smaller reporting company allows for certain exemptions from reporting requirements, reducing costs.

Negatives

• If a business combination is not completed within the timeframe, public shares will be redeemed at a per-share price based on the trust account balance, potentially less than the initial offering price.
• The company is dependent on completing a business combination to generate revenue.
• The company's management team has conflicts of interest due to other business ventures.

Risks

• The company may not be able to complete a business combination within the specified timeframe.
• The company may face competition from other entities seeking business combination opportunities.
• Third parties may bring claims against the company, reducing the funds available in the Trust Account.
• The company may be deemed an investment company under the Investment Company Act, leading to restrictions and compliance requirements.
• The company is dependent on its officers and directors, and their loss could adversely affect the company's ability to operate.
• The company's initial shareholders control a substantial interest and may exert influence in a manner not supported by other shareholders.
• The company may be a passive foreign investment company (PFIC), which could result in adverse U.S. federal income tax consequences to U.S. investors.
• Because the company is incorporated under the laws of the Cayman Islands, shareholders may face difficulties in protecting their interests.

Future Outlook

The company intends to complete a business combination, potentially with BridgeBio Oncology Therapeutics (BBOT), and operate the post-transaction business. If a business combination is not completed within the specified timeframe, the company will liquidate.

Industry Context

The document reflects the typical structure and operations of a special purpose acquisition company (SPAC) seeking to acquire a target business. The increasing number of SPACs has led to greater competition for attractive targets.

Comparison to Industry Standards

• The structure of Helix Acquisition Corp. II is similar to other SPACs, including the division of shares into Class A and Class B, the establishment of a trust account, and the requirement to complete a business combination within a specific timeframe.
• The agreement by the Sponsor, officers, and directors to waive redemption rights is a common feature in SPACs to ensure sufficient funds are available for the business combination.
• The requirement to obtain an opinion from an independent investment banking firm for affiliated transactions is a standard practice to ensure fairness.
• The company's classification as an emerging growth company and smaller reporting company is also typical for SPACs, allowing for reduced disclosure obligations.

Management Changes

Related Party Transactions

• The company pays the Sponsor $6,458 per month for office space, utilities, administrative services, and remote support services.
• The Sponsor purchased Private Placement Shares for $5,090,000.
• The Sponsor may provide Working Capital Loans to the company.

Stakeholder Impact

• Shareholders may have the opportunity to redeem their shares upon completion of a business combination.
• The company's success depends on completing a business combination that creates value for shareholders.
• The company's operations are subject to the laws and regulations of the Cayman Islands, which may differ from those of the United States.

Next Steps

• The company will seek shareholder approval for the proposed business combination with BridgeBio Oncology Therapeutics (BBOT).
• The company will work to satisfy the closing conditions outlined in the BBOT Business Combination Agreement.
• The company will continue to manage its finances and operations in preparation for the business combination or potential liquidation.

Key Dates

Keywords

business combination, ordinary shares, redemption rights, trust account, sponsor, directors, officers, securities, Class A, Class B, preference shares, SPAC, BBOT, PIPE